Boston Scientific Co. (NYSE:BSX) Stake Raised by Bfsg LLC

Bfsg LLC grew its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 2.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,684 shares of the medical equipment provider’s stock after purchasing an additional 163 shares during the period. Bfsg LLC’s holdings in Boston Scientific were worth $592,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Triad Wealth Partners LLC acquired a new stake in shares of Boston Scientific during the second quarter valued at approximately $26,000. First Foundation Advisors acquired a new stake in shares of Boston Scientific during the 1st quarter valued at $25,000. Eagle Bay Advisors LLC grew its holdings in shares of Boston Scientific by 542.1% during the 1st quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 309 shares in the last quarter. Lynx Investment Advisory purchased a new stake in shares of Boston Scientific during the second quarter worth $30,000. Finally, RiverPark Advisors LLC purchased a new position in Boston Scientific in the first quarter valued at about $30,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Truist Financial increased their price target on shares of Boston Scientific from $86.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, July 16th. Barclays boosted their price objective on Boston Scientific from $78.00 to $86.00 and gave the stock an “overweight” rating in a research report on Thursday, August 22nd. Argus boosted their price target on Boston Scientific from $80.00 to $95.00 and gave the company a “buy” rating in a research note on Tuesday, May 28th. Raymond James raised their target price on Boston Scientific from $85.00 to $91.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 25th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $85.00 price objective on shares of Boston Scientific in a research note on Thursday, July 25th. Three analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $85.24.

Boston Scientific Stock Up 1.4 %

NYSE BSX traded up $1.15 during mid-day trading on Thursday, hitting $80.67. The company’s stock had a trading volume of 5,476,710 shares, compared to its average volume of 6,095,126. The company’s 50 day simple moving average is $76.79 and its 200 day simple moving average is $72.76. Boston Scientific Co. has a twelve month low of $48.35 and a twelve month high of $80.96. The firm has a market capitalization of $118.35 billion, a price-to-earnings ratio of 67.79, a PEG ratio of 2.49 and a beta of 0.78. The company has a current ratio of 1.66, a quick ratio of 1.14 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.04. The company had revenue of $4.12 billion during the quarter, compared to analyst estimates of $4.02 billion. Boston Scientific had a return on equity of 16.80% and a net margin of 12.00%. The firm’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.53 EPS. Analysts anticipate that Boston Scientific Co. will post 2.4 earnings per share for the current year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $74.12, for a total value of $517,579.96. Following the completion of the transaction, the executive vice president now owns 40,188 shares in the company, valued at approximately $2,978,734.56. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold 20,949 shares of company stock valued at $1,583,395 over the last three months. Company insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.